List view / Grid view

Articles

Women in Stem with Andrea Pfeifer

30 November 2023 | By

This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…

Let’s talk neuroscience with Michelle Sidor at SFN

29 November 2023 | By

Drug Target Review’s Taylor Mixides met with Dr Michelle Sidor, the Director of Neuroscience at Alchemab Therapeutics, and Dr Sifis Pediaditakis at the Society for Neuroscience event this November. This exclusive interview explores neuroscientific research and its pivotal role in steering the company toward future triumphs. Michelle highlights the dynamic…

Exploring liver disease therapies  

29 November 2023 | By

Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline…

The role of STRIs in cancer

27 November 2023 | By

Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…

Discovering the principles of nervous system function

23 November 2023 | By

Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…

Combining autotaxin and TGF-β inhibitors in cancer

22 November 2023 | By

Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…

Natural killer cells: Looking good for cancer therapy

17 November 2023 | By

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?